CCL4 and Hepatic fibrosis: In 2017, IVA337, another new PPAR (including PPARA) agonist, revealed its ability to suppress the proliferation and activation of human hepatic stellate cells (HSCs), and alleviate mouse liver fibrosis induced by CCL4 (Wettstein et al., 2017).